These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11805368)

  • 1. Emerging issues in immunization.
    Havaldar PV
    Indian Pediatr; 2002 Jan; 39(1):106-7; author reply 108-11. PubMed ID: 11805368
    [No Abstract]   [Full Text] [Related]  

  • 2. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 3. Measles and rubella in the World Health Organization European region: diversity creates challenges.
    Spika JS; Wassilak S; Pebody R; Lipskaya G; Deshevoi S; Guris D; Emiroglu N
    J Infect Dis; 2003 May; 187 Suppl 1():S191-7. PubMed ID: 12721913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rubella immunization strategies in the state of São Paulo, Brazil.
    Rymkiewicz E; Zuzarte FC; de Oliveira Campos S; Pinto MI
    Bull World Health Organ; 2002; 80(3):258. PubMed ID: 11984616
    [No Abstract]   [Full Text] [Related]  

  • 5. Measles in Mexico, 1941-2001: interruption of endemic transmission and lessons learned.
    Santos JI; Nakamura MA; Godoy MV; Kuri P; Lucas CA; Conyer RT
    J Infect Dis; 2004 May; 189 Suppl 1():S243-50. PubMed ID: 15106118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles.
    Donald A; Muthu V
    Clin Evid; 2002 Jun; (7):331-40. PubMed ID: 12230657
    [No Abstract]   [Full Text] [Related]  

  • 7. [The epidemiological impact of vaccination strategies in the Lazio Region].
    Faustini A; Giorgi-Rossi P; Sangalli M; Spadea T; Perucci CA
    Ann Ig; 2002; 14(4 Suppl 4):39-49. PubMed ID: 12389423
    [No Abstract]   [Full Text] [Related]  

  • 8. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV infection and immunization.
    Paul Y
    Indian Pediatr; 2000 May; 37(5):559-60. PubMed ID: 10820557
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on active immunization in measles, mumps and rubella.
    Stokes J
    Johns Hopkins Med J; 1967 Nov; 121(5):314-28. PubMed ID: 6075620
    [No Abstract]   [Full Text] [Related]  

  • 12. IAP guidelines on optional vaccines and related matters.
    John TJ
    Indian Pediatr; 1999 Jul; 36(7):677-9. PubMed ID: 10740304
    [No Abstract]   [Full Text] [Related]  

  • 13. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States.
    Kolasa MS; Klemperer-Johnson S; Papania MJ
    J Infect Dis; 2004 May; 189 Suppl 1():S98-103. PubMed ID: 15106097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles-rubella mass immunization campaign in Albania, November 2000.
    Bino S; Kakarriqi E; Xibinaku M; Ion-Nedelcu N; Bukli M; Emiroglu N; Uzicanin A
    J Infect Dis; 2003 May; 187 Suppl 1():S223-9. PubMed ID: 12721917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rubella elimination programme strengthened through measles elimination programme in Catalonia.
    Domínguez A; Torner N; Martínez A; Costa J; Plans P; Ciruela P; Salleras L
    Vaccine; 2006 Feb; 24(9):1433-7. PubMed ID: 16226357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.